Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3/3b randomized observer-blind study of Fluad and Fluad Quadrivalent versus non-adjuvanted influenza vaccine in adults aged 65 years and older
2022-503004-24-00Phase 3Authorised
- Sponsor
- CSL Seqirus
- Start
- Oct 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, single-blind trial of Fluzone Trivalent, influenza virus type B (Victoria), Fluarix and Fluarix Quadrivalent in influenza (4 arms), sponsored by CSL Seqirus. Planned start Oct 2023; status: authorised.
02
Drugs
Fluzone Trivalentinfluenza virus type B (Victoria)FluarixFluarix Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on 2022-503004-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503004-24-00.